Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease.
Research output: Contribution to journal › Article
Debate exists regarding which endpoints most sensitively reflect day-to-day variation in chronic obstructive pulmonary disease (COPD) symptoms and are most useful in clinical practice to predict COPD exacerbations. We hypothesized that short-acting β2-agonist (SABA) reliever use would predict short- and long-term exacerbation risk in COPD patients.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||BMC Pulmonary Medicine|
|Publication status||Published - 2015|
No data available